Heres What Key Metrics Tell Us About MacroGenics Q3 Earnings
| MGNX Stock | USD 3.21 0.07 2.13% |
Slightly above 62% of MacroGenics' investor base is looking to short. The analysis of overall sentiment of trading MacroGenics stock suggests that many investors are alarmed at this time. MacroGenics' investing sentiment can be driven by a variety of factors including economic data, MacroGenics' earnings reports, geopolitical events, and overall market trends.
MacroGenics |
The headline numbers for MacroGenics give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read at zacks.com
 |
MacroGenics Fundamental Analysis
We analyze MacroGenics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MacroGenics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MacroGenics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
MacroGenics is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
MacroGenics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MacroGenics stock to make a market-neutral strategy. Peer analysis of MacroGenics could also be used in its relative valuation, which is a method of valuing MacroGenics by comparing valuation metrics with similar companies.
Peers
MacroGenics Related Equities
| MOLN | Molecular Partners | 4.23 | ||||
| PHVS | Pharvaris | 2.63 | ||||
| PMVP | Pmv Pharmaceuticals | 2.55 | ||||
| PTGX | Protagonist Therapeutics | 2.46 | ||||
| KZR | Kezar Life | 1.74 | ||||
| ZNTL | Zentalis Pharmaceuticals | 1.60 | ||||
| NKTX | Nkarta | 0.81 | ||||
| EWTX | Edgewise Therapeutics | 0.09 | ||||
| GLUE | Monte Rosa | 0.12 | ||||
| IPSC | Century Therapeutics | 1.59 | ||||
| PEPG | PepGen | 1.82 | ||||
| DAWN | Day One | 2.06 | ||||
| SNDX | Syndax Pharmaceuticals | 2.19 | ||||
| CCCC | C4 Therapeutics | 2.41 | ||||
| CGEM | Cullinan Oncology | 2.86 | ||||
| TYRA | Tyra Biosciences | 3.21 | ||||
| INZY | Inozyme Pharma | 3.58 | ||||
| ANTX | AN2 Therapeutics | 5.38 | ||||
| MLYS | Mineralys Therapeutics, | 5.79 |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.